UL54 foscarnet mutation in an hematopoietic stem cell transplant recipient with cytomegalovirus disease.

about

Progress in Treatment of Viral Infections in Children with Acute Lymphoblastic Leukemia Human cytomegalovirus antiviral drug resistance in hematopoietic stem cell transplantation: current state of the art.Treatment of CMV infection after allogeneic hematopoietic stem cell transplantation.

P2860

Q26740588-60BEE948-A968-4EDF-91AC-8F3F6B63A227 Q38779846-0B5653D8-028F-4AFD-9CF0-FDE4006DF9C7 Q38797660-EBCD0DF3-3405-4127-93FA-8225AA3803EC

P2860

UL54 foscarnet mutation in an hematopoietic stem cell transplant recipient with cytomegalovirus disease.

Item

http://www.wikidata.org/entity/Q42224425

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

UL54 foscarnet mutation in an ...... with cytomegalovirus disease.

@en

UL54 foscarnet mutation in an ...... with cytomegalovirus disease.

@nl

type

Item

label

UL54 foscarnet mutation in an ...... with cytomegalovirus disease.

@en

UL54 foscarnet mutation in an ...... with cytomegalovirus disease.

@nl

prefLabel

UL54 foscarnet mutation in an ...... with cytomegalovirus disease.

@en

UL54 foscarnet mutation in an ...... with cytomegalovirus disease.

@nl

P1476

UL54 foscarnet mutation in an ...... with cytomegalovirus disease.

@en

P2093

D R Kaul

http://www.w3.org/2001/XMLSchema#string

K Gregg

http://www.w3.org/2001/XMLSchema#string

M Hakki

http://www.w3.org/2001/XMLSchema#string

P2860

Antiviral drug resistance of human cytomegalovirus.

Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation.

Immunohistochemically proven cytomegalovirus end-organ disease in solid organ transplant patients: clinical features and usefulness of conventional diagnostic tests.

Use of foscarnet for cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation from a related donor.

Cytomegalovirus in hematopoietic stem cell transplant recipients: Current status, known challenges, and future strategies.

Foscarnet in the management of cytomegalovirus infections in hematopoietic stem cell transplant patients.

Cytomegalovirus drug resistance and clinical implications.

Beta-herpesvirus challenges in the transplant recipient.

Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates.

Clinical aspects of CMV infection after stem cell transplantation.

P304

320-323

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/TID.12200

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-03-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24621186

http://www.w3.org/2001/XMLSchema#string

P921

Cytomegalovirus

UL54 foscarnet mutation in an hematopoietic stem cell transplant recipient with cytomegalovirus disease.

about

P2860

P2860

UL54 foscarnet mutation in an hematopoietic stem cell transplant recipient with cytomegalovirus disease.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921